24th Int'l Prostate Cancer Update

24th cap update 24th Int'l. Prostate Cancer Update

February 19 - 22, 2014

Cascade Conference Center
Vail, Colorado USA

24th Int'l Prostate Cancer Update: Poster - PSA kinetics following robotic stereotactic body radiotherapy for localized prostate cancer

VAIL, CO USA (UroToday.com) - Presented by Thomas P. Kole, Leonard N. Chen, Joy S. Kim, Rudy Moures, Thomas Young, Siyuan Lei, Simeng Suy, Anatoly Dritschilo, John H. Lynch, and Sean P. Collins at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

24th Int'l Prostate Cancer Update: Poster - Finding occult prostatic cancer: The value of transperineal mapping biopsies and epigenetic assays

VAIL, CO USA (UroToday.com) - Presented by E. Francisco G. La Rosa, MD, Cliff Jones, DDS, Paul Arangua, E. David Crawford, MD, and Leander Van Neste, PhD at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

24th Int'l Prostate Cancer Update: Poster - Hematologic Safety of radium-223 dichloride (radium-223) in castration-resistant prostate cancer patients with bone metastases from the phase 3 ALSYMPCA trial: Baseline prognostic factor subgroup analysis

VAIL, CO USA (UroToday.com) - Presented by Joe M. O’Sullivan, Dimitris Voliotis, Dag Clement Johannessen, Anders Widmark, Isabel Syndikus, Nicholas James, Marcos Dall’Oglio, Ingvild Haugen, Andrew Cross, Jose Garcia- Vargas, and Nicholas Vogelzang at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

24th Int'l Prostate Cancer Update: Poster - Efficacy and safety of radium-223 dichloride (radium-223) in patients who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

VAIL, CO USA (UroToday.com) - Presented by Peter Hoskin, Mona Wahba, John Logue, David Bottomley, Sten Nilsson, Fang Fang, Jose Garcia-Vargas, Karin Staudacher, Paul Cislo, Jonathan Reuning-Scherer, and Christopher Parker at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

24th Int'l Prostate Cancer Update: Poster - Intermittent androgen deprivation with the gonadotrophin−releasing hormone (GnRH) antagonist degarelix

VAIL, CO USA (UroToday.com) - Presented by E. David Crawford, Neal Shore, Celestia Higano, Anders Neijber and Vladimir Yankov at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

24th Int'l Prostate Cancer Update: Abstract - Early clinical experience with the 17-gene Genomic Prostate Score for newly diagnosed prostate cancer

VAIL, CO USA (UroToday.com) - Introduction and Objective: A number of new diagnostic assays are being developed to improve risk stratification in prostate cancer (PCa), but their performance in “real-life” clinical practice remains to be determined.

24th Int'l Prostate Cancer Update: Abstract - Long-term results of focal therapy for prostate cancer

VAIL, CO USA (UroToday.com) - Introduction: The introduction of breast-sparing surgery (i.e., “lumpectomy”) revolutionized the management of breast cancer. The use of lumpectomy showed that quality of life could be optimized without compromising treatment efficacy.

24th Int'l Prostate Cancer Update: Abstract - Efficacy and safety of radium-223 dichloride (radium-223) in patients who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

VAIL, CO USA (UroToday.com) - Background: Radium-223 is the first alpha-emitter approved by both the US Food and Drug Administration and European Commission for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases.

24th Int'l Prostate Cancer Update: Abstract - Role of optical spectroscopy in the diagnosis of prostatic cancer

VAIL, CO USA (UroToday.com) - Light interacts with biological tissue in a variety of ways. The optical properties of tissues are determined by their molecular composition and cellular morphology.

24th Int'l Prostate Cancer Update: Abstract - Intermittent androgen deprivation with the gonadotrophin−releasing hormone (GnRH) antagonist degarelix

VAIL, CO USA (UroToday.com) - Background: For men with prostate cancer requiring androgen suppression, intermittent androgen deprivation (IAD) has been proposed as an alternative to continuous androgen deprivation (CAD).

24th Int'l Prostate Cancer Update: Abstract - Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents

VAIL, CO USA (UroToday.com) - Background: Two oral agents have recently been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC): abiraterone acetate (AA) combined with prednisone (P) for treatment of patients with mCRPC and enzalutamide (ENZ) for patients with mCRPC previously treated with docetaxel.

24th Int'l Prostate Cancer Update: Abstract - Prostate cancer patients demonstrate adherence to medication while on abiraterone acetate (AA) therapy

VAIL, CO USA (UroToday.com) - Background: Oral medications have become more widely available for treatment of various cancers, and adherence to dosing/ refill patterns, or medication possession, are important considerations for treatment.

24th Int'l Prostate Cancer Update: Abstract - Unsuspected metastases found during screening for a trial of patients with non-metastatic castration resistant prostate cancer

VAIL, CO USA (UroToday.com) - Background: Factors associated with rates of progression from non-metastatic to metastatic castration resistant prostate cancer (CRPC) have been described.[1, 2]

24th Int'l Prostate Cancer Update: Abstract - Cost considerations for new oral therapies for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel

VAIL, CO USA (UroToday.com) - Background: Abiraterone acetate (AA) and enzalutamide (EN) are two novel oral agents approved for use in docetaxel-treated mCRPC patients.

24th Int'l Prostate Cancer Update: Abstract - Effect of a 22-marker genomic classifier assay on adjuvant radiation therapy recommendations in patients with high-risk prostate cancer

VAIL, CO USA (UroToday.com) - Background: Clinical guidelines recommend adjuvant radiation therapy (ART) be offered to patients with adverse pathology after radical prostatectomy (RP).

24th Int'l Prostate Cancer Update: Abstract - Robotic prostatectomy and the ambulatory surgery center – A transition to outpatient care

VAIL, CO USA (UroToday.com) - Introduction: Since Clayman performed the first laparoscopic nephrectomy in 1991, laparoscopy has revolutionized operative urology and allowed for marked reductions in postoperative pain and duration of hospital stay.

24th Int'l Prostate Cancer Update: Abstract - Hematologic Safety of radium-223 dichloride (radium-223) in castration-resistant prostate cancer patients with bone metastases from the phase 3 ALSYMPCA trial: Baseline prognostic factor subgroup analysis

VAIL, CO USA (UroToday.com) - Background: Radium-223 is a targeted alpha-emitter that selectively binds to bone metastases with high-energy, short-range (< 100 μm) alpha-particles, and is approved by the US Food and Drug Administration and European Commission for treatment of patients with CRPC, symptomatic bone metastases, and no known visceral metastatic disease.

24th Int'l Prostate Cancer Update: Abstract - PSA kinetics following robotic stereotactic body radiotherapy for localized prostate cancer

VAIL, CO USA (UroToday.com) - Objectives: Stereotactic Body Radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer.

24th Int'l Prostate Cancer Update: Abstract - Degarelix monotherapy vs. luteinizing hormone-releasing hormone agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer

VAIL, CO USA (UroToday.com) - Background: Short-term antiandrogen (AA) flare protection is used to counter the clinical effects of the testosterone surge associated with luteinizing hormone-releasing hormone (LHRH) agonist therapy.

24th Int'l Prostate Cancer Update: Abstract - Cell cycle progression-combined risk score stratifies prostate cancer risk and significantly modifies treatment decisions in prostate cancer

 

VAIL, CO USA (UroToday.com) - Background: The cell cycle progression combined risk (CCP-CR) test (Prolaris™, Myriad Genetic Laboratories, Inc.) has been validated in eight cohorts and provides information on the risk of prostate cancer-specific disease progression and disease specific mortality when combined with standard clinicopathologic parameters.

Page 1 of 2
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe